Librela (also known as Bedinvetmab) is a monoclonal antibody therapy for dogs, specifically designed for the treatment of osteoarthritis (OA). It works by targeting and neutralizing nerve growth factor (NGF), which plays a crucial role in the transmission of pain signals associated with osteoarthritis.
Here’s how Bedinvetmab works:
- Targeting NGF: Nerve growth factor (NGF) is a protein that plays a key role in the perception of pain. In osteoarthritis, increased levels of NGF contribute to heightened pain sensitivity and inflammation in affected joints. Bedinvetmab specifically targets and binds to NGF, preventing it from interacting with its receptors and thereby reducing pain signaling.
- Reducing Pain and Inflammation: By blocking the action of NGF, Bedinvetmab helps to reduce pain and inflammation associated with osteoarthritis in dogs. This can lead to improved mobility, increased activity levels, and an overall enhancement in the quality of life for affected dogs.
- As is true of most arthritis treatments, Librela does not treat or cure the arthritis itself but rather reduces the pain and inflammation that it causes. A cure for arthritis remains elusive.
Librela represents a novel approach to managing osteoarthritis in dogs and provides an additional treatment option for veterinarians and pet owners. As with any medication, it’s essential to use Librela under the guidance and supervision of a veterinarian, who can determine if it’s an appropriate treatment option for your dog based on factors such as the dog’s medical history, severity of arthritis symptoms, and overall health status. It is not indicated for dogs with neurological impairments even if arthritis is also present.
For more information: https://www.zoetispetcare.com/products/librela
Elizabeth F. Baird, DVM, CVPP, CCRT, cVMA
Steele Pain Management & Rehabilitation Center
